Dinutuximab Beta at the HUS and the Toulouse Oncopole

Dinutuximab Beta at the Strasbourg University Hospitals (HUS) and the Toulouse Oncopole: Comparative Analysis of Patient Pathways, Associated Costs and Quality of Life According to Traditional Hospitalization or Hospital at Home (HAD)

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06275334

Acronym

DNB

Enrollment

Registered

2024-02-23

Start date

2023-11-28

Completion date

2024-11-28

Last updated

2024-02-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neuroblastoma

Keywords

Neuroblastoma, Dinutuximab Beta, DNB

Brief summary

In this study the investigators wish to describe the cohort of pediatric patients suffering from neuroblastoma and treated with Dinutuximab and to compare the costs and quality of life between the two French centers, the University Hospital of Strasbourg (HUS) and the Oncopole of Toulouse.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

2 Years to 25 Years

Inclusion criteria

* Subjects aged 2 years to 25 years * Male or female gender * Subjects suffering from neuroblastoma and treated at the HUS or at the Oncopole center in Toulouse during the period from January 1, 1998 to December 31, 2023. * Subject (and/or holders of parental authority) not opposing, after information, the reuse of the child's data for the purposes of this research and agreeing to respond to the quality of life survey.

Exclusion criteria

* Patient or parents of the minor having expressed their opposition to participating in the study. * specific clinical forms of the disease, * interfering treatments and associated diseases.

Design outcomes

Primary

Measure	Time frame	Description
Comparison of two methods of treating a pediatric pathology in two French health establishments, the HUS and the Oncopole of Toulouse.	The period concerned is from January 1, 1998 to December 31, 2023.	This study is retrospective and consists of comparing two methods of treating neuroblastoma in two health establishments and covers the period from January 1, 1998 to December 31, 2023.

Countries

France

Contacts

Primary ContactAnne EL AATMANI, Pharm, PhD

Anne.ELAATMANI@chru-strasbourg.fr33 3 88 12 78 06

Outcome results